Description
CJC-1295 (NO DAC) & Ipamorelin Blend 10mg: Research-Grade Peptide for Laboratory Studies
The CJC-1295 (NO DAC) & Ipamorelin Blend 10mg is a high-purity, research-grade peptide combination designed exclusively for controlled laboratory studies of the somatotropic axis and growth hormone regulation. This product is intended strictly for scientific research and is not approved for human consumption, clinical use, or veterinary applications.
Vial contents. This vial holds both compounds together, blended before lyophilisation. If you need either on its own, CJC-1295 without DAC and Ipamorelin are stocked separately.
What is CJC-1295 (NO DAC)?
CJC-1295 (NO DAC) is a synthetic analog of Growth Hormone Releasing Hormone (GHRH). It is a shorter-acting variant of CJC-1295 without the Drug Affinity Complex (DAC), allowing researchers to study growth hormone dynamics with more precise temporal control.
GHRH-Receptor Activity: Characterised at the GHRH receptor in laboratory models.
Shorter Half-Life: Suited to controlled experiments focused on acute peptide activity and growth hormone modulation.
What is Ipamorelin?
Ipamorelin is a synthetic growth hormone secretagogue characterised in experimental models as selective for the GHS-R1a receptor relative to other endocrine pathways.
Selective GH Stimulation: Used in research to study growth hormone pathways without significantly altering other hormones.
Laboratory Applications: Suitable for in vitro, ex vivo, or other controlled experimental models focused on GH secretion dynamics.
Key Research Applications of CJC-1295 (NO DAC) & Ipamorelin Blend
Growth Hormone Pathway Research: Designed for studies investigating GH release mechanisms in laboratory settings.
Somatotropic Axis Models: Enables exploration of GHRH and GH secretagogue interactions under controlled experimental conditions.
Controlled Experimental Protocols: Supports both single-dose and multi-dose laboratory studies.
Peptide Dynamics: Facilitates research into short-term and repeated peptide effects on GH secretion in models.
Why Choose CJC-1295 (NO DAC) & Ipamorelin Blend 10mg?
This 10mg research peptide blend is manufactured under strict laboratory-grade quality standards to ensure consistency and reproducibility for scientific experiments.
High-Purity Formulation: Ensures reliability for all research protocols.
Flexible Laboratory Use: Suitable for a variety of experimental designs in growth hormone regulation studies.
Controlled Research Applications: Not intended for human or veterinary use.
Quality Assurance & Purity Testing Guarantee
We provide a purity testing guarantee for all batches of CJC-1295 (NO DAC) & Ipamorelin Blend 10mg. Researchers are encouraged to verify the peptide’s purity via third-party accredited laboratories. If results indicate deviations from stated purity, a full refund and reimbursement of testing costs will be provided.
COA: 3P Tested Content Results: CJC-1295 (MOD-GRF 1-29) | 6.07 mg, Ipamorelin | 4.83 mg | View Test
Important Legal Disclaimer
For Research Purposes Only
The CJC-1295 (NO DAC) & Ipamorelin Blend 10mg is strictly intended for laboratory use and scientific research. It is not for human consumption, clinical, or veterinary applications and is not approved by the FDA, Health Canada, or any other regulatory authority for therapeutic use. By purchasing, you confirm that this product will be used exclusively for research in compliance with applicable laws and regulations.
Compound identity and specification
CJC-1295 (NO DAC) & IPAMORELIN BLEND 10mg is a blend, so identity is given per component. Each formula, mass and registry number below is verified against PubChem and can be looked up directly.
| Component | Sequence | Formula | Mass (g/mol) | CAS |
|---|---|---|---|---|
| CJC-1295 without DAC (Mod GRF 1-29) CID 56841945 | [D-Ala2, Gln8, Ala15, Leu27]-GRF(1-29) amide | C152H252N44O42 | 3367.9 | 863288-34-0 |
| Ipamorelin CID 9831659 | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | C38H49N9O5 | 711.9 | 170851-70-4 |
| Total peptide content | 10 mg total — CJC-1295 without DAC 5 mg, Ipamorelin 5 mg |
|---|---|
| Physical form | Lyophilised powder in a sealed vial |
| Analysis | Third-party HPLC; the result for this product is published on this page |
| Supplied for | Laboratory research use only |
Analytical note — CJC-1295 without DAC (Mod GRF 1-29). This is the version without the drug-affinity complex. CJC-1295 with DAC is a different molecule, C165H269N47O46 at about 3,647 g/mol, CAS 446262-90-4 – a difference of roughly 280 Da. The two are the most commonly confused pair in this category, and the mass on the certificate is what separates them.
Analytical note — Ipamorelin. Three of the five residues are non-standard: alpha-aminoisobutyric acid, D-2-naphthylalanine and D-phenylalanine. Amino-acid analysis after hydrolysis cannot distinguish D from L, so composition analysis alone does not confirm this sequence; identity rests on mass and on the synthesis route.
Identity references The molecular formula, molecular mass and CAS registry number above are taken from the PubChem record linked in the table, not from a supplier datasheet, so every figure can be checked against an independent source in one click. Sequences are given as reported in the peptide literature, in the one-letter or three-letter convention as appropriate, with any non-standard residue named in full. Where a compound exists in more than one form — a free peptide and a metal complex, a fragment and its parent protein, a modified and an unmodified analog — the form supplied is the one identified here, and the mass on the certificate of analysis is what distinguishes it.
Research Literature
Peer-reviewed studies involving this compound and its class. All findings listed are from in vitro, cell culture or animal models and are provided for scientific reference only. This product is supplied for laboratory research and is not approved for human consumption, clinical, or veterinary use.
- Jette L, et al. Endocrinology. 2005;146(7):3052-3058. In cultured rat anterior pituitary cells and Sprague-Dawley rats, measured GH secretion, Cys34-albumin conjugate formation and resistance to DPP-IV cleavage. Source · PMID 15817669
- Alba M, et al. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. In GHRH-knockout mice, measured pituitary GH and IGF-I expression. Source · PMID 16822960
- Raun K, et al. Eur J Endocrinol. 1998;139(5):552-561. In primary rat pituitary cell culture, anaesthetised rats and conscious swine, measured GH release and the absence of concomitant ACTH and cortisol elevation. Source · PMID 9849822
- Johansen PB, et al. Growth Horm IGF Res. 1999;9(2):106-113. In rats, measured longitudinal bone growth following administration. Source · PMID 10373343
- Svensson J, et al. J Endocrinol. 2000;165(3):569-577. In adult female rats, characterised the response to chronic secretagogue exposure; see the linked record for endpoints. Source · PMID 10828840
The third-party report for this material is published on this page, and every certificate we hold is collected on the certificates of analysis page.
Related Research Compounds
Browse more compounds in GHS, or view the full research peptide catalogue.
Leigh (verified owner) –
Arrived on time and very professional looking labels with primo quality products… I’ve ordered from Exolabs a few times now and never had an issue… highly recommend A++.
Earl (verified owner) –
It arrived super fast. The package was on point and sealed in good condition